A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc.
NeoImmuneTech
Tizona Therapeutics, Inc
Essen Biotech
Nouscom SRL
University of California, San Diego
Novartis
Inhibrx Biosciences, Inc
Sairopa B.V.
Coherus Oncology, Inc.
Rondo Therapeutics
Astellas Pharma Inc
Mirati Therapeutics Inc.
Trishula Therapeutics, Inc.
NuCana plc
Medicenna Therapeutics, Inc.
Trishula Therapeutics, Inc.
DEKA Biosciences
Intensity Therapeutics, Inc.
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Carisma Therapeutics Inc
Merck Sharp & Dohme LLC
Eli Lilly and Company
Astellas Pharma Inc
Astellas Pharma Inc
Salubris Biotherapeutics Inc
ENB Therapeutics, Inc
National Cancer Institute (NCI)
Mural Oncology, Inc
Kineta Inc.
M.D. Anderson Cancer Center
Oncorus, Inc.
Sheba Medical Center
RenJi Hospital
Syndax Pharmaceuticals
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
KitovPharma
Pancreatic Cancer Research Team